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Chronic diseases have assumed an increasingly
important role in public health research and interven-
tion. Without treatment, depressive disorders charac-
teristically assume a chronic course and are expected,
by 2020, to be second only to heart disease in the glob-
al burden of disease. Thus, understanding the relation-
ship between depressive disorders and chronic disease
appears vital to public health assessment and health
care delivery. 
Methods
Articles for review were primarily identified by a
Medline search emphasizing the subject headings mental
disorders or depression crossed with selected chronic dis-
eases and conditions including asthma, arthritis, cardio-
vascular disease, cancer, diabetes, and obesity. 
Results
Mental illnesses — most specifically, depressive disor-
ders — were associated with increased prevalence of
chronic diseases. This association between depression and
chronic disease appears attributable to depressive disor-
ders precipitating chronic disease and to chronic disease
exacerbating symptoms of depression. The complex inter-
relationship between depressive disorders and chronic dis-
ease has important implications for both chronic disease
management and the treatment of depression.
Conclusion
Depressive disorders assume an important role in the
etiology, course, and outcomes associated with chronic dis-
ease. Multivariate community-based research and inter-
vention fostering the detection and treatment of depres-
sive disorders is needed, as is further examination of the
role exerted by mental illnesses other than depression in
the pathogenesis of chronic disease.
Introduction
Recent research indicates that seven out of 10 office
visits to a primary care practitioner concern chronic dis-
eases (1). As the management of chronic diseases has
assumed an increasingly vital role in health care deliv-
ery, recognition of the importance of depressive disor-
ders has also grown. By 2020, depression is expected to
be second only to heart disease as a source of the global
burden of disease (2). As chronic disease and depressive
disorders are increasingly recognized as major impedi-
ments to health, understanding the connection between
them becomes of utmost importance to providing quality
health care.
Despite the growing recognition of the importance of
both chronic disease and depressive disorders to the
health of individuals and communities, research exam-
ining their interrelationship has been the subject of sur-
prisingly little empirical review. A Medline search for
literature reviews emphasizing both chronic disease and
depression yielded only two publications. These articles
addressed factors germane to health-service costs (3)
and individual characteristics precipitating the onset of
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depressive disorders subsequent to the development of
chronic disease (4). While raising important concerns,
previous reviews were deliberately limited in scope and
did not generally address disease-specific variables poten-
tially underlying the associations between depressive dis-
orders and a number of chronic diseases. To better
address this issue, we reviewed the research literature
examining the relationships between depressive disorders
and prevalent chronic diseases that are also of program-
matic relevance to the work of the Centers for Disease
Control and Prevention.
Methods
Articles included in this review were primarily identi-
fied through a Medline search of the terms mental disor-
ders or depression crossed with the chronic diseases and
conditions asthma, arthritis, cardiovascular disease, can-
cer, diabetes, and obesity. These chronic diseases were
selected because they have been identified as highly
prevalent and as major sources of morbidity and mortali-
ty among U.S. adults. Studies included for review were
generally limited to empirical investigations that provid-
ed definitional or diagnostic criteria for both depression




Nearly 50% of asthma patients may suffer from clinical-
ly significant depressive symptoms (5), which have been,
in part, attributed to the stress of having a chronic illness
(6). In particular, persons with asthma who experience dis-
ruptive symptoms, such as dyspnea and nighttime awak-
ening, are at increased risk for major depression (7). The
presence of depression among persons with asthma
assumes particular gravity because increased depressive
symptoms have been associated with poorer asthma out-
comes (8), such as impaired voluntary activation of the
diaphragm (9). In clinical samples of children and 
adolescents, asthma has been associated with the presence
of an anxiety disorder (10) and with anxious depressive 
symptoms among youth with moderate and severe 
persistent asthma (11).
It appears that the symptoms — rather than the diagno-
sis — of asthma are associated with depression or anxiety
(12): 87.5% of persons with frequent asthma attacks mani-
fest psychopathology, compared with 25% of persons with
less frequent attacks (13). Similarly, among persons whose
asthma is difficult to control, psychopathology — primarily
anxiety and depressive symptoms — was associated with
more frequent visits to primary care providers and emer-
gency departments and with more hospitalizations (14).
Psychological morbidity is associated with poor adherence
to medication regimens (15), and mothers of children with
asthma are at risk for increased depressive symptoms (16).
Early assessment and intervention addressing depressive
disorders improves treatment adherence and outcomes and
may also decrease mortality (17).
Cognitive behavioral therapy (CBT) — in which the indi-
vidual is instructed to monitor and challenge self-negating
thoughts — has yielded a significant decrease in asthma
symptoms and depression (18). Likewise, physical inactiv-
ity has been speculated to augment the strength of the
association between perceived stressors and depression in
persons with asthma, suggesting that exercise may ame-
liorate this association and decrease the likelihood of
depression in this population (19).
Arthritis
Depression and/or anxiety are among the most common-
ly reported concerns by persons with arthritis (20).
Screening of patients with arthritis revealed that depres-
sion was associated with activity restriction, further sug-
gesting that nonpsychiatric physicians should be aware of
the mental health status of patients with chronic illnesses
(21). Persons with arthritis experiencing arthritis-based
disability (22) and the recurrence of arthritic symptoms
(23) reported greater depression. Research on adolescents
and young adults with arthritis has found that functional
status is significantly correlated with depression, 
self-esteem, and loneliness (24); significantly greater
depression was reported among those experiencing more
severe symptoms (24).
Research on the Arthritis Self-Management Program
found that participation in this intervention had a pos-
itive effect on perceptions of self-efficacy, communica-
tion with physicians, fatigue, anxiety, pain, and depres-
sion (25). A randomized trial of an intervention
designed to improve mood (antidepressant medications
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and/or six to eight sessions of psychotherapy) improved
depression and fostered improvements in functional
status and quality of life (26). CBT has proven particu-
larly effective in ameliorating depressive symptoms
when initiated early in the course of rheumatoid arthri-
tis (27) and when tailored to the concerns reported by
persons with rheumatoid arthritis, such as fatigue or
mood (28). Similarly, antidepressant medication has
been associated with significant improvements in both
psychological status and health status in persons with
rheumatoid arthritis (29).
Rest and inactivity were previously considered to be rea-
sonable therapeutic approaches in the management of
osteoarthritis until it was recognized that physical inac-
tivity contributed to disability and impaired functioning.
Subsequent research suggests that a tailored program of
aerobic or resistance-based exercise may be an important
component of self-managing osteoarthritis (30). Aerobic
exercise has been found to both ameliorate depressive
symptoms and to reduce disability and pain among per-
sons with arthritis (31).
Cardiovascular disease
Depressive disorders have been associated with risk fac-
tors for cardiovascular disease (CVD), such as smoking
and physical inactivity (32), and mental illness, in gener-
al, has been associated with increased mortality due to
CVD (33). In general, persons who are depressed are
much more likely to develop coronary artery disease (34),
and meta-analyses reveal that the relative risk for devel-
oping heart disease in individuals with depression or
depressive symptoms is approximately 1.6 times greater
than among nondepressed persons (35,36), which is more
than the risk conferred by passive smoking (36). A
stronger effect size was reported for clinical depression
than for depressive symptoms, suggesting the presence of
a dose-response relationship (35). Depression has been
positively associated with the metabolic syndrome among
women (but not men) younger than 40 years (37), sug-
gesting that early detection and treatment of depression
may potentially forestall the risk of cardiovascular dis-
ease among women.
Depression or depressive symptoms are also predictive
of stroke (38): persons with significant depressive symp-
toms are approximately twice as likely as those with few
depressive symptoms to have a stroke within 10 years (39).
Moreover, depression is associated with an increased risk
for stroke morbidity and mortality (40).
In addition to being a predictor of stroke, depression
commonly develops after a stroke, especially after a stroke
affecting the left hemisphere of the brain (41). More than
half of patients experiencing a stroke report depressive
symptoms within 18 months of having a stroke (42). Post-
stroke depression has been associated with impairments
in response to rehabilitation (43) and with increased mor-
tality up to two years following the stroke (44).
Antidepressant treatment of post-stroke depression is
warranted and, in addition to alleviating depression, may
foster recovery of cognitive function (45) and significantly
increase survival (46).
Depressive disorders also appear related to the occur-
rence of heart attack, or myocardial infarction (MI).
Persons with a history of major depression are more
than four times as likely to have an MI than those with
no history of depression (47), and high levels of 
depressive symptoms are associated with an increased
risk of MI (48).
Approximately one in six persons who have experienced
an MI suffer from major depression, and at least twice that
many experience significant depressive symptoms (49).
Patients who have had an MI and are also depressed have
more medical comorbidities (50) and cardiac complications
(51) and are at greater risk for mortality (52) than their
nondepressed peers. Increased mortality is also evident in
persons who had an MI and who manifest very low levels
of depressive symptoms (53), underscoring the importance
of mental health to physical health outcomes.
Persons with depression following an MI are less like-
ly to adhere to recommended lifestyle and behavioral
changes, potentially increasing their risk for subsequent
cardiac events (54). This is particularly unfortunate
because cardiac rehabilitation has been found to
improve depressive symptoms (55). However, the use of
a specific class of antidepressant medications — the
selective serotonin reuptake inhibitors (SSRIs) — may,
in addition to their beneficial effect on depression, exert
antiplatelet effects protecting against MI (56). In addi-
tion to being safer in overdose (57), SSRIs are also less
likely to induce arrhythmia than other classes of antide-
pressant medications (58). It has further been concluded
that the combination of CBT with an SSRI is frequently
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the most effective treatment of depression in persons
with CVD (59).
Cancer
Estimates of the prevalence of psychiatric disorders
among persons with cancer vary widely, depending on the
type of cancer and its clinical stage. Previous research
indicates that nearly 50% of patients newly admitted to a
cancer center met diagnostic criteria for a psychiatric dis-
order. Adjustment disorders — distress related to a specif-
ic precipitant — comprised 68% of these diagnoses,
although many of those diagnosed reported anxiety or
depression as a central symptom (60). Among cancer
patients judged terminally ill, 53% met psychiatric diag-
nostic criteria, with delirium — a fluctuating change in
cognition and disturbance in consciousness — being the
most frequently diagnosed disorder (61).
In addition to delirium, cancer patients also suffer from
depression and anxiety (62); 21% of cancer patients are
reported to be depressed (63). Depression assumes partic-
ular significance in the care of individuals with cancer,
because it has been associated with a desire for hastened
death among terminally ill cancer patients (64), and
increased depressive symptoms are inversely related to
survival (65). Of cancer patients in an intensive care unit
who were assessed as being at high risk for hospital death,
40% reported depression (66), suggesting that diagnosis
and treatment of depression are inadequate. Strikingly,
among cancer patients undergoing chemotherapy and
experiencing anemia-related fatigue, improved hemoglo-
bin levels have been reported to reduce depressive symp-
toms (67), further suggesting the importance of physical
health to mental health status.
A previous survey of psychotropic prescription prac-
tices at five major oncology centers revealed hypnotics to
be the most widely prescribed drugs, with antidepres-
sants comprising only 1% of psychotropic prescriptions
(68). Subsequent research, however, has indicated an
increase of antidepressant use in community cancer
care, with 19.2% of breast, 11% of colon, and 13.7% of
lung cancer patients receiving antidepressants during a
two-year interval (69).
Despite the observation that both antidepressants and
psychotherapy are effective in treating depression in
patients with cancer, research on antidepressant pharma-
cotherapy and psychotherapy among persons with cancer
has been characterized as largely lacking randomized
placebo-controlled trials (70). Moreover, antidepressant
prescription has been found to be associated with factors
not specifically related to psychopathology, such as patient
age or the presence of pain (69), and some speculate that
most depressed patients with cancer do not need medica-
tion (71). This belief, however, may reflect the misconcep-
tion that depression is a “natural” response to cancer and
does not merit systematic diagnosis and treatment (72).
Research suggests that depression in persons with can-
cer is amenable to treatment. Among cancer patients with
a life expectancy of at least 12 months, CBT has been asso-
ciated with significantly decreased depressive symptoms
across a four-month interval (73). CBT has also been 
associated with decreased pain, reduced symptomatic dis-
tress (74), and subsequent improvement in cellular
immune function (75).
Adoption of a depression screening program and antide-
pressant algorithm by oncologists resulted in significant
improvements in mood and quality of life among cancer
patients (76). Similarly, a placebo-controlled trial of anti-
depressant medication in advanced cancer patients
demonstrated that antidepressant therapy decreased
depressive symptoms and improved patient assessments
of quality of life (77). In addition to reducing the risk of
depression, data suggest that physical activity may also
decrease the risk of colon, breast, and lung cancer (78).
Diabetes
Elevated rates of depression have consistently been
associated with diabetes (79), with results of a meta-
analysis indicating depression is twice as prevalent
among persons with diabetes than it is among persons
without diabetes (80). While it has been proposed that
depressive symptoms may be a risk factor for the devel-
opment of diabetes, this association is most pronounced
at high levels of depressive symptoms and, interestingly,
only observed among persons with less than a high school
education (81). These findings suggest that factors asso-
ciated with low socioeconomic status may contribute to
the development of diabetes among persons with sub-
stantial depressive symptoms.
Comorbid depressive symptoms or depression among
persons with diabetes have been associated with adapta-
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tion to the illness (82), diabetic-related complications (79),
unemployment (83), and illness intrusiveness, a construct
defined as the degree to which diabetes disrupts valued
activities and interests (84). As is true in the general pop-
ulation, depression was more prevalent among women
than among men with diabetes (80,85) and among younger
adults (85). Depressive symptoms are more likely to per-
sist among persons with multiple diabetic-related compli-
cations and those with less than a high school education
(79). In a prospective community-based study, baseline
depressive symptoms were positively associated with
fasting insulin levels and physical inactivity (86). A diag-
nosis of diabetes and self-reported depression were posi-
tively associated with sedentariness in both bivariate
and multivariate analyses (87). Compared with their
nondepressed peers, patients with diabetes who were
diagnosed with depression were more likely to report fre-
quent overeating of sweets and high-fat foods and were
less satisfied with their ability to adhere to a diabetic diet
away from home (88).
Despite the availability of measures to screen for depres-
sion, it is estimated that less than 25% of those with
depression are diagnosed and treated (89). This is particu-
larly disconcerting because the treatment of depression
appears to be associated with improved glycemic control
(90). Furthermore, because depression is associated with
diabetic complications (91), treatment of depression may
also reduce diabetes-related disability. Compared with
their nondepressed peers, persons with diabetes and
depression have higher ambulatory-care use and fill more
prescriptions. Total health expenditures for persons with
diabetes and depression were 4.5 times higher than for
those without depression: $247 million compared with $55
million (85).
Research has revealed that both CBT (90) and antide-
pressant pharmacotherapy (92) are associated with
decreased severity of depression among persons with dia-
betes and with improved glycemic control. Thus, in addi-
tion to preventing needless suffering, the treatment of
depression among persons with diabetes offers the added
promises of substantial financial savings and improved
medical care of these individuals.
Obesity
Several studies have indicated an association between
psychopathology, including depressive symptoms, and
high body mass index (BMI), or obesity. The relationship
between obesity and psychopathology differs among men
and women, with a BMI $30 among women associated
with nearly a 50% increase in the lifetime prevalence of
depressive disorders compared with nonobese women (93).
In contrast, while BMI has not been found to be related to
measures of mental well-being among men, abdominal
obesity or a high waist/hip ratio has been associated with
an increased prevalence of both depressive symptoms (94)
and antidepressant medication use (95).
Although it is important to note that most overweight
or obese persons do not suffer from mood disorders (96),
significant positive associations have been reported
between BMI and depressive symptoms (97). It has
been posited that a common pathophysiology may
underlie both obesity and depression. The neurotrans-
mitters serotonin and norepinephrine are involved in
regulating both mood and body weight and, logically, in
the treatment of both depression and obesity (98).
Antidepressant medications available before the devel-
opment of SSRIs frequently induced weight gain; newer
agents generally do not stimulate appetite, thus making
them potentially useful in depressed patients who do
not wish to gain weight (99).
Previous longitudinal research has examined the rela-
tionship between depressive symptoms or psychological
well-being and weight gain. Women who were either nor-
mal weight or overweight at baseline and who had experi-
enced a recent weight gain scored lower on a measure of
psychological well-being than women who had not gained
weight (100). Similarly, persons who were overweight and
depressed at baseline demonstrated a significantly
increased likelihood of subsequent weight gain relative to
those who were not depressed. Among the highest quintile
of baseline BMI, this relationship was stronger among
women (with an odds ratio of 2.2) than men (with an odds
ratio of 1.3) (101).
Cognitive behavioral interventions have been useful in
managing obesity, largely by modifying eating behaviors
and dietary choices in addition to decreasing psychological
distress and sedentariness (102). In addition to fostering
weight loss, CBT has been found to improve self-reported
mental health among obese persons (103). However, psy-
chosocial difficulties have been associated with weight
gain following initial weight loss among obese individuals
who had received CBT (104), with long-term CBT compli-
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ance being particularly low among persons with binge-eat-
ing behaviors (105).
Strikingly, children and adolescents with major depres-
sive disorder appear to manifest an increased risk for sub-
sequently becoming overweight (96), suggesting that both
depressive disorders and their treatment are relevant to
the prevalence of obesity. The relationship between obesi-
ty and depressive disorders thus appears to be reciprocal,
with advances in the recognition and treatment of each of
these diseases potentially fostering improved mental and
physical health.
Discussion
Research examining the association between depressive
disorders and chronic disease suggests that timely diagno-
sis and treatment of psychiatric disorders could greatly
affect the impact of chronic disease. The presence of men-
tal illness may be an important contributor to the etiology
of chronic disease. Thus, the promotion of mental health
would likely result in reducing a considerable proportion of
the burden of chronic disease. Similarly, the presence of
depressive disorders often adversely affects the course and
complicates the treatment of chronic disease. It is impor-
tant to remember that untreated depressive disorders
characteristically assume a chronic course (106), thereby
adding to the burden of chronic disease in their own right.
Multivariate investigation of the associations among
depressive disorders, chronic disease, and a variety of
medical and sociodemographic characteristics would pro-
vide valuable insights into contemporary notions of health
and quality of life.
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